Compare · COO vs RXST
COO vs RXST
Side-by-side comparison of The Cooper Companies Inc. (COO) and RxSight Inc. (RXST): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both COO and RXST operate in Ophthalmic Goods (Health Care), so they compete in similar markets.
- COO is the larger of the two at $19.03B, about 92.7x RXST ($205.3M).
- RXST has been more active in the news (10 items in the past 4 weeks vs 4 for COO).
- Both have 25 recent analyst ratings on file.
- Company
- The Cooper Companies Inc.
- RxSight Inc.
- Price
- -
- -
- Market cap
- $19.03B
- $205.3M
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Ophthalmic Goods
- Ophthalmic Goods
- Exchange
- NYSE
- NASDAQ
- IPO
- 2021
- News (4w)
- 4
- 10
- Recent ratings
- 25
- 25
The Cooper Companies Inc.
The Cooper Companies, Inc. operates as a medical device company worldwide. It operates through two segments, CooperVision and CooperSurgical. The company develops, manufactures, and markets a range of contact lenses, including spherical lenses, and toric and multifocal lenses that correct near- and farsightedness, as well as addresses various complex visual defects, such as astigmatism and presbyopia. It also provides range of products and services for enhancing health of women, babies, and families, including medical devices, fertility, genomics, and diagnostics and contraception for hospitals and surgical centers, obstetricians' and gynecologists' (OB/GYNs) medical offices, and fertility clinics. In addition, the company develops mechanical surgical solutions for skin closure; and offers PARAGARD, a contraceptive, as well as provides assisted reproductive technology products, genetic screening and testing, and products within the general OB/GYN offerings. It markets its products under Biofinity, clariti 1day, MyDay, Avaira Vitality, and Proclear 1 Day brand name through a network of field sales representatives, independent agents, eye care practitioners, and distributors. The Cooper Companies, Inc. was founded in 1980 and is headquartered in San Ramon, California.
RxSight Inc.
RxSight, Inc., a medical technology company, develops light adjustable lens (LAL) to improve uncorrected visual acuity that can be adjusted enhance uncorrected visual acuity after cataract surgery. It also offers RxSight light delivery device, an office-based light treatment device that delivers UV light in a programmed pattern to modify the LAL based on the visual correction needed to achieve desired vision after cataract surgery. RxSight, Inc. was formerly known as Calhoun Vision, Inc. and changed its name to RxSight, Inc. in February 2017. The company was incorporated in 1997 and is based in Aliso Viejo, California.
Latest COO
- SEC Form 10-Q filed by The Cooper Companies Inc.
- Needham reiterated coverage on Cooper with a new price target
- SEC Form 8-K filed by The Cooper Companies Inc.
- CooperCompanies Announces Second Quarter 2026 Results
- SEC Form SD filed by The Cooper Companies Inc.
- CooperVision Names Muru Annamalai as President, Asia-Pacific
- The Cooper Companies Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure
- CooperCompanies Appoints Paul Keel to its Board of Directors
- CooperCompanies Announces Release Date for Second Quarter 2026
- SEC Form 4 filed by Rosebrough Walter M Jr
Latest RXST
- Director Warner Robert Keith was granted 37,037 shares, increasing direct ownership by 90% to 78,076 units (SEC Form 4)
- Director Palmisano Robert J was granted 37,037 shares, increasing direct ownership by 90% to 78,076 units (SEC Form 4)
- Director Maniar Shweta was granted 37,037 shares, increasing direct ownership by 204% to 55,172 units (SEC Form 4)
- Director Fountain Tamara was granted 37,037 shares, increasing direct ownership by 104% to 72,582 units (SEC Form 4)
- Director Link William J Phd was granted 37,037 shares, increasing direct ownership by 98% to 74,892 units (SEC Form 4)
- Director Corley Jesse Anderson was granted 37,037 shares, increasing direct ownership by 75% to 86,227 units (SEC Form 4)
- Director Cohen Raymond W was granted 30,864 shares, increasing direct ownership by 87% to 66,532 units (SEC Form 4)
- Director Tammenoms Bakker Juliet was granted 37,037 shares, increasing direct ownership by 77% to 85,183 units (SEC Form 4)
- Director Andrews Julie was granted 37,037 shares, increasing direct ownership by 90% to 78,076 units (SEC Form 4)
- RxSight Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders